Neuren Pharmaceuticals 過去の業績
過去 基準チェック /56
Neuren Pharmaceuticalsは、平均年間80.5%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間35.4% 82%収益成長率で 成長しています。 Neuren Pharmaceuticalsの自己資本利益率は53.5%であり、純利益率は60.7%です。
主要情報
80.5%
収益成長率
79.9%
EPS成長率
Pharmaceuticals 業界の成長 | 31.2% |
収益成長率 | 82.0% |
株主資本利益率 | 53.5% |
ネット・マージン | 60.7% |
前回の決算情報 | 30 Jun 2024 |
最近の業績更新
Recent updates
New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)
Nov 11Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up
Nov 08Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Oct 24Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Aug 29Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now
Aug 14Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today
May 31Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely
May 03An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued
Apr 01Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically
Mar 05Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors
Mar 02Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors
Dec 18Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues
Sep 02Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Aug 31This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year
Mar 03Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)
Feb 19Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?
Jan 04収支内訳
収支内訳
Neuren Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Jun 24 | 193 | 117 | 5 | 0 |
31 Mar 24 | 213 | 137 | 6 | 0 |
31 Dec 23 | 232 | 157 | 6 | 0 |
30 Sep 23 | 155 | 106 | 5 | 0 |
30 Jun 23 | 78 | 55 | 4 | 0 |
31 Mar 23 | 47 | 28 | 4 | 0 |
31 Dec 22 | 15 | 0 | 3 | 0 |
30 Sep 22 | 9 | -3 | 3 | 0 |
30 Jun 22 | 3 | -7 | 3 | 0 |
31 Mar 22 | 3 | -7 | 3 | 0 |
31 Dec 21 | 3 | -8 | 2 | 0 |
30 Sep 21 | 2 | -10 | 2 | 0 |
30 Jun 21 | 1 | -12 | 2 | 0 |
31 Mar 21 | 1 | -11 | 2 | 0 |
31 Dec 20 | 1 | -9 | 2 | 0 |
30 Sep 20 | 1 | -8 | 2 | 0 |
30 Jun 20 | 0 | -8 | 2 | 0 |
31 Mar 20 | 0 | -9 | 2 | 0 |
31 Dec 19 | 0 | -11 | 2 | 0 |
30 Sep 19 | 7 | -6 | 2 | 0 |
30 Jun 19 | 14 | -1 | 2 | 0 |
31 Mar 19 | 14 | 1 | 2 | 0 |
31 Dec 18 | 14 | 3 | 2 | 0 |
30 Sep 18 | 7 | 3 | 2 | 0 |
30 Jun 18 | 1 | 3 | 1 | 0 |
31 Mar 18 | 1 | 3 | 2 | 0 |
31 Dec 17 | 1 | 3 | 2 | 0 |
30 Sep 17 | 2 | -2 | 2 | 0 |
30 Jun 17 | 3 | -8 | 2 | 0 |
31 Mar 17 | 3 | -10 | 2 | 0 |
31 Dec 16 | 3 | -12 | 2 | 0 |
30 Sep 16 | 2 | -14 | 2 | 0 |
30 Jun 16 | 0 | -15 | 3 | 0 |
31 Mar 16 | 1 | -14 | 3 | 0 |
31 Dec 15 | 2 | -13 | 3 | 0 |
30 Sep 15 | 2 | -11 | 3 | 0 |
30 Jun 15 | 3 | -9 | 3 | 0 |
31 Mar 15 | 3 | -9 | 3 | 0 |
31 Dec 14 | 3 | -8 | 3 | 0 |
30 Sep 14 | 3 | -10 | 2 | 0 |
30 Jun 14 | 3 | -12 | 2 | 0 |
31 Mar 14 | 4 | -11 | 2 | 0 |
31 Dec 13 | 5 | -10 | 2 | 0 |
質の高い収益: NEUは 高品質の収益 を持っています。
利益率の向上: NEUの現在の純利益率 (60.7%)は、昨年(70.3%)よりも低くなっています。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: NEU過去 5 年間で収益を上げており、収益は年間80.5%増加しています。
成長の加速: NEUの過去 1 年間の収益成長率 ( 113.1% ) は、5 年間の平均 ( 年間80.5%を上回っています。
収益対業界: NEUの過去 1 年間の収益成長率 ( 113.1% ) はPharmaceuticals業界46.5%を上回りました。
株主資本利益率
高いROE: NEUの 自己資本利益率 ( 53.5% ) は 傑出している と考えられます。